Cannabis for Vaping

Recruiting in Palo Alto (17 mi)

Overseen by Dustin Lee, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Johns Hopkins University

No Placebo Group

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of electronic cigarettes. The study's goals are to test demand for e-cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke e-cigarettes and either smoke or vape THC in the laboratory.

Eligibility Criteria

This trial is for individuals who use e-cigarettes and smoke or vape THC. Participants must be willing to try different doses of THC in a controlled lab setting. Specific eligibility criteria are not provided, but typically include age range, health status, and frequency of cannabis and tobacco use.

Inclusion Criteria

Must report daily use of e-cigarettes

I have used cannabis through inhalation before.

Must have biological confirmation of cannabis use: positive urinary THC drug test at screening

Exclusion Criteria

Must meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine

Must report current intention to reduce or quit cannabis or tobacco use within the next 30 days

Must have a positive breath alcohol test at study admission

Participant Groups

The study examines how various doses of THC (high dose, low dose, no THC) affect the desire for e-cigarettes with full nicotine or placebo nicotine. It measures cravings, mood changes, heart rate, blood pressure, breath carbon monoxide levels, and thinking skills.

Group I: Vaporized THC Experimental Treatment 5 Interventions

Each participant in this arm will receive 0, 5, and 30mg of THC over the course of six visits. Each participant will also receive e-cigarette containing 0% and 5.0% nicotine.

Group II: Smoked THC Experimental Treatment 5 Interventions

Each participant in this arm will receive 0, 5, and 30mg of THC over the course of six visits. Each participant will also receive e-cigarette containing 0% and 5.0% nicotine.

THC is already approved in United States, Canada, European Union for the following indications:

🇺🇸 Approved in United States as Dronabinol for:

• Appetite loss and weight loss in HIV
• Nausea and vomiting from chemotherapy

🇨🇦 Approved in Canada as Dronabinol for:

• Appetite loss and weight loss in HIV/AIDS
• Nausea and vomiting from chemotherapy

🇪🇺 Approved in European Union as Dronabinol for:

• Appetite loss and weight loss in HIV/AIDS
• Nausea and vomiting from chemotherapy

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Johns Hopkins University Behavioral Pharmacology Research Unit Baltimore, MD

Who Is Running the Clinical Trial?

Johns Hopkins University Lead Sponsor

National Institute on Drug Abuse (NIDA) Collaborator

References